{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:38:11Z","timestamp":1769503091343,"version":"3.49.0"},"reference-count":0,"publisher":"Il Pensiero Scientifico Editore","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:p>Summary. Background. Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria and progressive impairment in renal function. Pentoxifylline is a non-specific inhibitor of phosphodiesterase with anti-inflammatory properties which may have therapeutic potency in patients with diabetic kidney disease. Objective. The present study is aimed at evaluating the efficacy of pentoxifylline as a treatment strategy for alleviating the microalbuminuria in type-2 diabetic patients with nephropathy. Methods. This double-blind randomized clinical trial was performed on outpatients with type 2 diabetic nephropathy who presented urine albumin excretion of 30-300 mg per 24 hours on at least three consecutive occasions. A total of 58 patients were randomly assigned to the treatment and control groups. The treatment group (n=29) received pentoxifylline (400 mg\/day) for 3 months in addition to the standard drugs for diabetic nephropathy (Raas blockers), while the control group (n=29) received placebo as add-on therapy. Finally, urine albumin test was measured before and after 3 months of treatment and compared between the two groups. Results. Before the intervention, no significant difference in the levels of albuminuria was observed between the two groups (153.21\u00b1130.80 mg\/day vs. 159.93 \u00b1130.45; p=0.845); but after 12 weeks of treatment, albuminuria in the treatment group was significantly reduced compared to the placebo group (29.59 \u00b127.88 mg\/day vs. 160.48\u00b1129.53 mg\/day; p&lt;0.0001). At the end of the study, the response rate to treatment (more than 50% reduction in albuminuria) was 89.7% in the pentoxifylline group, while no response to treatment was observed in the placebo group (p&lt;0.0001). Conclusions. Pentoxifylline as add-on therapy to the conventional treatment (Raas blockers) may reduce the microalbuminuria in patients with diabetic nephropathy without any side effects.<\/jats:p>","DOI":"10.1701\/4169.41640","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T22:16:08Z","timestamp":1769465768000},"source":"Crossref","is-referenced-by-count":0,"title":["Determination of pentoxifylline efficacy on microalbuminuria in patients with type-2 diabetes"],"prefix":"10.1701","volume":"115","author":[{"given":"Shokouh","family":"Shayanpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aslan","family":"Mehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Hayati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrnoosh","family":"Zakerkish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Seifollah","family":"Beladi Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khojasteh","family":"Hoseinynejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"55112","container-title":["Recenti Progressi in Medicina"],"original-title":[],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T22:16:08Z","timestamp":1769465768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.recentiprogressi.it\/articoli.php?archivio=yes&vol_id=4169&id=41640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1701\/4169.41640","relation":{},"ISSN":["0034-1193"],"issn-type":[{"value":"0034-1193","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}